Trial Profile
Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms RITUX-ERAH
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress
- 09 Nov 2015 Results published in the Transplantation
- 10 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.